BACKGROUND & AIMS: Several studies have shown that new direct-acting antivirals maintain their efficacy in liver transplant (LT) recipients with severe hepatitis C virus (HCV) recurrence. We determined the clinical impact of sofosbuvir/ribavirin in LT through the changes in liver function and fibrosis state at 24 and 48 weeks after treatment. METHODS: Between June 2014 and July 2015, 126 patients (30 F3, 96 F4 Metavir stage) were enrolled to receive sofosbuvir + ribavirin (24 weeks, 118 patients) or sofosbuvir + simeprevir + ribavirin (12 weeks, 8 patients); treatment was initiated at a median time of 4.3 years from LT. Median follow-up after therapy completion was 461 days. RESULTS: All 30 F3 patients achieved a sustained virological response at week 24 after treatment (SVR24) and showed a distinct amelioration of the AST-to-platelet ratio index (APRI), FIB-4 and liver stiffness at elastography by week 24 post-therapy, which were maintained at week 48. Of the 96 F4 cirrhotic patients, 72 (75%) achieved SVR24 accompanied by significant improvement of liver function, which was maintained at week 48 (Child B-C 22% baseline, 11% week 24, 7% week 48); APRI, FIB-4 and liver stiffness further improved significantly between weeks 24 and 48 of follow-up. Among the 77 responders (27 F3, 50 F4) who underwent elastography at baseline and at the end of follow-up, 39 (50.6%; 18 F3, 21 F4) exhibited a regression in fibrosis stage. CONCLUSION: At about 1 year from the completion of successful sofosbuvir-based therapy, patients with post-LT HCV and severe fibrosis experienced a long-term liver function improvement accompanied by a regression of fibrosis stage in half of them.

Impact of viral eradication with sofosbuvir-based therapy on the outcome of post-transplant hepatitis C with severe fibrosis

MARTINI, Silvia;SACCO, Marco;STRONA, Silvia;ARESE, Daniele;TANDOI, FRANCESCO;STRADELLA, Davide;RIZZA, Giorgia;MOSCHINI, Pamela Mariangela;AMOROSO, Antonio;RIZZETTO, Mario;SALIZZONI, Mauro;SARACCO, Giorgio Maria;ROMAGNOLI, Renato
Last
2017

Abstract

BACKGROUND & AIMS: Several studies have shown that new direct-acting antivirals maintain their efficacy in liver transplant (LT) recipients with severe hepatitis C virus (HCV) recurrence. We determined the clinical impact of sofosbuvir/ribavirin in LT through the changes in liver function and fibrosis state at 24 and 48 weeks after treatment. METHODS: Between June 2014 and July 2015, 126 patients (30 F3, 96 F4 Metavir stage) were enrolled to receive sofosbuvir + ribavirin (24 weeks, 118 patients) or sofosbuvir + simeprevir + ribavirin (12 weeks, 8 patients); treatment was initiated at a median time of 4.3 years from LT. Median follow-up after therapy completion was 461 days. RESULTS: All 30 F3 patients achieved a sustained virological response at week 24 after treatment (SVR24) and showed a distinct amelioration of the AST-to-platelet ratio index (APRI), FIB-4 and liver stiffness at elastography by week 24 post-therapy, which were maintained at week 48. Of the 96 F4 cirrhotic patients, 72 (75%) achieved SVR24 accompanied by significant improvement of liver function, which was maintained at week 48 (Child B-C 22% baseline, 11% week 24, 7% week 48); APRI, FIB-4 and liver stiffness further improved significantly between weeks 24 and 48 of follow-up. Among the 77 responders (27 F3, 50 F4) who underwent elastography at baseline and at the end of follow-up, 39 (50.6%; 18 F3, 21 F4) exhibited a regression in fibrosis stage. CONCLUSION: At about 1 year from the completion of successful sofosbuvir-based therapy, patients with post-LT HCV and severe fibrosis experienced a long-term liver function improvement accompanied by a regression of fibrosis stage in half of them.
37
62
70
http://www.wiley.com/bw/journal.asp?ref=1478-3223
Direct-acting antivirals; HCV recurrence; Liver transplantation; Non-invasive fibrosis tests; Survival
Martini, Silvia; Sacco, Marco; Strona, Silvia; Arese, Daniele; Tandoi, Francesco; Dell Olio, Dominic; Stradella, Davide; Cocchis, Donatella; Mirabella, Stefano; Rizza, Giorgia; Magistroni, Paola; Moschini, Pamela; Ottobrelli, Antonio; Amoroso, Antonio; Rizzetto, Mario; Salizzoni, Mauro; Saracco, Giorgio M.; Romagnoli, Renato
File in questo prodotto:
File Dimensione Formato  
LIVint-16-00427.R2.pdf

Accesso aperto

Descrizione: Articolo principale
Tipo di file: PREPRINT (PRIMA BOZZA)
Dimensione 844.01 kB
Formato Adobe PDF
844.01 kB Adobe PDF Visualizza/Apri
Martini_et_al-2016-Liver_International.pdf

Accesso riservato

Descrizione: Articolo principale
Tipo di file: PDF EDITORIALE
Dimensione 394.12 kB
Formato Adobe PDF
394.12 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1611544
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 29
  • ???jsp.display-item.citation.isi??? 24
social impact